Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022

Fineline Cube Dec 12, 2022

China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...

Company Deals

Roche and Zhongshan Hospital Collaborate on Clinical Studies and Innovation Center

Fineline Cube Dec 12, 2022

Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a...

Company Drug

ASH 2022: China Biotechs Showcase Latest Clinical Trial Results

Fineline Cube Dec 12, 2022

The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...

Company Deals R&D

Merck Partners with Tsinghua Shenzhen for Organoid 3D Printing System

Fineline Cube Dec 12, 2022

Germany giant Merck (NYSE: MRK) struck a three-year partnership with Tsinghua Shenzhen International Graduate School,...

Company Deals

Luye Pharma Group Hands Over Seroquel Distribution Rights to DCH Auriga in Singapore

Fineline Cube Dec 12, 2022

China-based Luye Pharma Group announced that it is handing Singapore distribution and marketing rights to...

Company Drug

RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers

Fineline Cube Dec 9, 2022

China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...

Company Drug

Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022

Fineline Cube Dec 9, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...

Policy / Regulatory

NMPA Extends Validation Period for COVID-19 Antigen Detection Reagents

Fineline Cube Dec 9, 2022

The National Medical Products Administration released a notification extending the validation period of approvals for...

Company Deals

Science Standard Medical Testing Raises Pre-Series A Funding

Fineline Cube Dec 9, 2022

Science Standard Medical Testing, a professional third-party testing institution based in Changzhou, reportedly raised “tens...

Company Deals

Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199

Fineline Cube Dec 9, 2022

Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...

Company Deals

XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development

Fineline Cube Dec 9, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai...

Company Drug

Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma

Fineline Cube Dec 9, 2022

Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...

Company Deals

Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer

Fineline Cube Dec 9, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu...

Company Deals

Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech

Fineline Cube Dec 9, 2022

Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...

Company Deals

ExoNeuglia Secures Angel Funding for iPSC-Based Cell Therapy

Fineline Cube Dec 8, 2022

ExoNeuglia, a stem-cell-focused biotech based in Suzhou, reportedly raised “tens of millions” of renminbi in...

Company Drug

Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation

Fineline Cube Dec 8, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s...

Company Drug

CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials

Fineline Cube Dec 8, 2022

China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...

Policy / Regulatory

24 Provinces Form Alliances for Volume-Based Procurement of Medical Consumables

Fineline Cube Dec 8, 2022

The Henan provincial alliance procurement office released a notification indicating that 24 provinces/regions will form...

Company Deals

Yuanmai Cell Biotechnology Secures Angel Funding for Macrophage Immunotherapy

Fineline Cube Dec 8, 2022

Yuanmai Cell Biotechnology Co., Ltd, a macrophage immunotherapy developer based in Nanjing, reportedly raised “tens...

Company Deals

Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics

Fineline Cube Dec 8, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the...

Posts pagination

1 … 615 616 617 … 692

Recent updates

  • Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement
  • Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721
  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.